ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 2558

Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)

Robert B.M. Landewé1, Désirée van der Heijde2, Maxime Dougados3, Xenofon Baraliakos4, Filip van Den Bosch5, Bengt Hoepken6, Karen Thomas6 and Lianne S. Gensler7, 1Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, 4Ruhr-University Bochum, Herne, Germany, 5Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, 6UCB Pharma, Monheim, Germany, 7University of California, San Francisco, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: anti-TNF therapy, axial spondyloarthritis, certolizumab pegol and remission

Session Information

Date: Tuesday, October 23, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained remission after 48 weeks’ (wks’) treatment. Here, we report interim efficacy and safety data for both subpopulations from the ongoing trial.

Methods:

Up to wk48, C-OPTIMISE (NCT02505542) was open-label (Part A), followed by 48-wk parallel-group, double-blind, placebo-controlled treatment (full dose and half dose) to wk96 (Part B). Patients with adult-onset axSpA of <5 years’ duration, fulfilling ASAS classification criteria, were recruited. Part A: patients received CZP (400mg at wks0/2/4, then 200mg Q2W); patients achieving sustained remission (ASDAS<1.3 at wk32 and <2.1 at wk36 [or vice versa], and <1.3 at wk48) were eligible for Part B (secondary outcome). Primary outcome (not reported): percentage of patients in Part B not experiencing a flare. Missing values were imputed using non-responder imputation (NRI) and last observation carried forward (LOCF).

Results:

Part A: Of 736 patients (Table 1), 43.9% achieved sustained remission (r-axSpA/AS: 42.8%; nr-axSpA: 45.3%; NRI). At baseline, 98.5% patients had high/very high disease activity (ASDAS≥2.1); at Wk48, 52.7% (r-axSpA/AS: 52.6%; nr-axSpA: 52.9%) had inactive disease (ASDAS<1.3; LOCF; Table 2). The treatment-emergent adverse event (TEAE) rate/100 patient-years’ exposure was 224.2; 3.9% patients discontinued CZP due to TEAEs. No new safety signal was identified.

Conclusion:

The run-in phase of C-OPTIMISE shows that similar and substantial proportions of patients with r-axSpA/AS and nr-axSpA achieved sustained remission during 48 wks’ CZP treatment. No new safety signal was identified.

The study was funded by UCB Pharma, medical writing by Hinal Tanna, Costello Medical, UK. We thank the patients who contributed.

 

 


Disclosure: R. B. M. Landewé, Abbott, Amgen, Centocor, Pfizer, Roche, Schering-Plough, UCB Pharma, Wyeth, 2, 5, 8,Ablynx, AstraZeneca, GlaxoSmithKline, 5,Novartis, 2, 5,Merck, Bristol Myers Squibb, 5, 8; D. van der Heijde, Imaging Rheumatology BV, 3,AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB Pharma, 5; M. Dougados, AbbVie, Eli Lilly, Merck, Novartis, Pfizer, UCB Pharma, 2, 5; X. Baraliakos, AbbVie, Bristol-Myers Squibb, Celgene, Chugai, Janssen, MSD, Novartis, Pfizer and UCB Pharma, 2, 5, 8; F. van Den Bosch, AbbVie, Bristol Myers-Squibb, Celgene, Janssen, Merck, Novartis, Pfizer and UCB Pharma, 5, 8; B. Hoepken, UCB Pharma, 3; K. Thomas, UCB Pharma, 3,Karen Thomas Statistics Limited, 4; L. S. Gensler, UCB Pharma, 2.

To cite this abstract in AMA style:

Landewé RBM, van der Heijde D, Dougados M, Baraliakos X, van Den Bosch F, Hoepken B, Thomas K, Gensler LS. Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-and-safety-outcomes-in-patients-with-axial-spondyloarthritis-treated-with-certolizumab-pegol-results-from-the-48-week-run-in-part-of-a-withdrawal-study-nct02505542/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-outcomes-in-patients-with-axial-spondyloarthritis-treated-with-certolizumab-pegol-results-from-the-48-week-run-in-part-of-a-withdrawal-study-nct02505542/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology